From the Editors: Those in Thoracic Oncology Field Must Educate Themselves About Artificial Intelligence
Witold K. Rzyman, MD, PhD+more
Like it or not, AI will be part the diagnostic and therapeutic landscape, and it is incumbent on clinicians to understand its implications, limitations, and benefits, ILCN editors say. Read more
Tumor Treating Fields May Provide Additional Treatment Option for mNSCLC Following Progression
Erin JungmeyerInvestigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
International Group Consensus Statement Offers Technical Guidance for MPM Imaging
Sharyn Katz MD, MTR+more
Dr. Sharyn Katz and colleagues summarize key recommendations for improving imaging quality in malignant pleural mesothelioma. Read more
The newly elected board members, including President-Elect Dr. Caicun Zhou, will assume their roles at the upcoming 2023 World Conference on Lung Cancer in Singapore. Read more
Canada to require health warnings on cigarettes. US FDA approves application for pemetrexed injection, grants priority review for repotrectinib. Read more
ADAURA Demonstrates OS Benefit with Adjuvant Osimertinib in Resectable EGFRm NSCLC
Erin JungmeyerDr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more
Data Supporting IO Before Surgery in Resectable NSCLC Grows
Erin JungmeyerDuring ASCO’s 2023 Annual Meeting investigators shared findings from several neoadjuvant studies, including KEYNOTE-671 and Neotorch, which showed improved EFS with pembrolizumab and toripalimab, respectively. Read more
From the Editors: Defining Resectability of Non-Small Cell Lung Cancer in 2023
Witold K. Rzyman, MD, PhD+more
Is “resectability” based on radical resection criteria still valid in the era of neoadjuvant immunochemotherapy? ILCN’s editors say the term needs to be revisited and probably redefined based on a tumor’s status before treatment and after neoadjuvant treatment. Read more
Majority of NSCLC Patients from Low Socio-Economic Areas in England Do Not Receive Novel Anti-Cancer Therapies
Erin JungmeyerDespite access to free treatment within the National Health Service, patients in the most deprived areas were 55% less likely to receive targeted therapies, biologic treatments, and immunotherapy compared to residents in the least deprived areas. Read more
Commentary: Global Initiatives to Reduce Cancer Incidence, Mortality Must Tackle Tobacco
Carolyn Dresler, MD, MPA+more
Carolyn Dresler, MD, MPA, and Chris Bostic, JD, say plans to reduce the prevalence and impact of lung cancer must address smoking if they are to succeed. Read more